International Council for Harmonisation (ICH)
Consultations
On this page:
| Document | Type of Notice | File Number | Consultation Start Date | Consultation End Date |
|---|---|---|---|---|
| Notice to Stakeholders - Consultation on the Impacts of Implementation of ICH M13A: Bioequivalence for Immediate Release Solid Oral Dosage Forms | Consultation | 24-111353 - 179 | January 17, 2025 | March 3, 2025 |
| Release of draft (Step 2) ICH Guideline E6(R3) Annex 2: Good Clinical Practice | Consultation | 24-110987-619 | December 20, 2024 | March 20, 2025 |
| Release of draft (Step 2) ICH Guideline M15: Model Informed Drug Development | Consultation | 24-110987-619 | December 20, 2024 | March 20, 2025 |
Please note that draft (step 2) guidelines are only available in English; however, guidelines finalised by the ICH will be translated into French and will be made available upon request. It is also important to note that amendments to draft documents may occur as a result of regulatory consultations and subsequent deliberations within the ICH.
All comments forwarded to Health Canada will be transmitted to the ICH as is, with the disclaimer that they are provided for information and do not necessarily represent the views of Health Canada, except as specifically indicated in separate comments.
As appropriate, your organization may alternatively wish to provide comments to your affiliate association internationally for their input directly to ICH.
Please use the ICH template for public consultations to send in your comments. Comments provided to Health Canada should be submitted by the date listed in the table above in order to allow sufficient time for their assessment and subsequent transmission to the ICH.
Comments should be directed to:
Health Canada - ICH Coordinator
E-mail: ich@hc-sc.gc.ca
Recent/upcoming public consultation meetings
| Topic | Type of Meeting | File Number | Additional Notes |
|---|---|---|---|
| Health Canada and United States Food and Drug Administration Joint Public Consultation on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guidelines | Joint Public Consultation | 22-108413-148 |
This public consultation for Canadian and U.S. stakeholders will take place virtually on February 11, 2025 from 11:00 AM EST to 3:00 PM EST. Please see below for additional information. |
Health Canada and the U.S. Food and Drug Administration (FDA) are holding joint annual public consultation meetings on International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines currently under development. The aim of this initiative is to hold public consultation meetings prior to biannual ICH face-to-face meetings, in order to seek input on certain regulatory aspects that could be beneficial for the harmonisation of ICH guidelines. Stakeholder input received through this initiative will be considered in current or future guideline development. Health Canada also intends to use these opportunities to better understand areas in drug product regulation where Canadian requirements may differ from those in place in the U.S., with a view to minimizing these differences.
In preparation for the next ICH Assembly meeting, a public consultation for Canadian and U.S. stakeholders will place virtually on February 11, 2025 from 11:00 AM EST to 3:00 PM EST.
The agenda for the meeting is now available and registration is open on the registration page. For additional information, including Concept Papers and any available draft guidelines for comment, please visit the ICH Website.
For enquiries please email: ich@hc-sc.gc.ca.
Page details
- Date modified: